Combining Puma Biotechnology’s candidate therapy PB272, also known as neratinib, with the chemotherapy drug Xeloda (capecitabine) appears to have therapeutic potential for patients with advanced HER2-positive breast cancer and brain metastasis, who were not previously treated with ... Read more